SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    Akaike L.T., Yoshida M., Miyamoto Y., Sato K., Kohno M., Sasamoto K., Miyazaki S., Ueda S., Maeda H. (1993) Antagonistic action of imidazolineoxyl N-oxide against endothelium relaxing factor/NO through a radical reaction. Biochemistry 32,827832.
  • 2
    Alam Z.I., Jenner A., Daniel S.E., Lees A.J., Cairns N., Marsden C.D., Jenner P., Halliwell B. (1997 a) Oxidative DNA damage in the parkinsonian brain : an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J. Neurochem. 69,11951203.
  • 3
    Alam Z.I., Daniel S.E., Lees A.J., Marsden C.D., Jenner P. , and Halliwell. (1997 b) A generalised increase in protein carbonyls in the brain in Parkinson's but not incidental Lewy body disease. J. Neurochem. 69,13261329.
  • 4
    Banati R.B., Daniel S.E., Blunt S.B. (1998) Glial pathology but absence of apoptotic nigral neurons in long-standing Parkinson's disease.Mov. Disord. 13,221227.
  • 5
    Barker R. & Johnson A. (1995) Nigral and striatal neurons, inNeural Cell Culture—A Practical Approach (Cohen J. and Wilkin G. P., eds), pp. 2539. IRL Press, Oxford.
  • 6
    Beal F. (1998) Excitotoxicity and nitric oxide in Parkinson's disease pathogenesis, inBeyond the Decade of the Brain, Vol. 3 : Neuroprotection in Parkinson's Disease (Olanow W. C. and Jenner P., eds), pp. 215222. Wells, Medical Ltd., Royal Tunbridge Wells, U.K.
  • 7
    Boka C., Anglade P., Wallach D., Javoy-Agid F., Hirsch E.C. (1994) Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease.Neurosci. Lett. 172,151154.
  • 8
    Bolaños J.P., Peuchen S., Heales S.J.R., Land J.M., Clark J.B. (1994) Nitric oxide-mediated inhibition of the mitochondrial respiratory chain in cultured astrocytes.J. Neurochem. 63,910916.
  • 9
    Bolaños J.P., Heales S.J.R., Peuchen S., Barker J.E., Land J.M., Clark J.B. (1996) Nitric oxide-mediated mitochondrial damage : a potential role for glutathione.Free Radic. Biol. Med. 21,9951001.
  • 10
    Bronstein D.M., Perez-Otano I., Sun V., Sawin M., Chan J., Wu G., Hudson P.M., Kong L., Hong J., McMillan M.K. (1995) Glia-dependent neurotoxicity and neuroprotection in mesencephalic cultures.Brain Res. 704,112116.
  • 11
    Castaño A., Herrera A.J., Cano J., Machado A. (1998) Lipopolysaccharide intranigral injection induces inflammatory reaction and damage in nigrostriatal dopaminergic system.J. Neurochem. 70,15841592.
  • 12
    Chao C.C., Hu S., Peterson P.K. (1996 a) Glia : the not so innocent bystanders. J. Neurovirol. 2,234239.
  • 13
    Chao C.C., Hu S., Sheng W.S., Bu D., Bukrinsky M.I., Peterson P.K. (1996 b) Cytokine-stimulated astrocytes damage human neurons via a nitric oxide mechanism. Glia 16,276284.
  • 14
    Dawson V.L., Brahmbhatt H.P., Mong J.A., Dawson T.M. (1994) Expression of inducible nitric oxide synthase causes delayed neurotoxicity in primary mixed neuronal-glial cortical cultures.Neuropharmacology 33,14251430.
  • 15
    Desagher S., Glowinski J., Premont J. (1996) Astrocytes protect neurons from hydrogen peroxide toxicity.J. Neurosci. 16,25532568.
  • 16
    Dexter D.T., Carayon A., Javoy-Agid F., Agid Y., Wells F.R., Daniel S.E., Jenner P., Marsden C.D. (1991) Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.Brain 114,19531975.
  • 17
    Dexter D.T., Holley A.E., Flitter W.D., Slater T.F., Wells R.F., Daniel S.E., Lees A.J., Jenner P., Marsden C.D. (1994) Increased levels of lipid hydroperoxides in the parkinsonian substantia nigra : an HPLC and ESR study.Mov. Disord. 9,9297.
  • 18
    Dringen R. & Hamprecht B. (1997) Involvement of glutathione peroxidase and catalase in the disposal of exogenous hydrogen peroxide by cultured astroglial cells.Brain Res. 759,6775.
  • 19
    Drukarch B., Schepens E., Jongenelen C.A.M., Stoof J.C., Langeveld C.H. (1997) Astrocyte-mediated enhancement of neuronal survival is abolished by glutathione deficiency.Brain Res. 770,123130.
  • 20
    Forno S. (1981) Pathology of Parkinson's disease, inMovement Disorders, Neurology 2 (Marsden C. D. and Fahn S., eds), pp. 2140. Butterworth Scientific, London.
  • 21
    Griffith M.J.D., Messent M., MacAllister R.J., Evans T.W. (1993) Aminoguanidine selectively inhibits inducible nitric oxide synthase.Br. J. Pharmacol. 110,963968.
  • 22
    Halliwell B. (1996) Mechanisms involved in the generation of free radicals.Pathol. Biol. (Paris) 44,613.
  • 23
    Hirsch E.C., Hunot S., Damier P., Faucheux B. (1998) Glial cells and inflammation in Parkinson's disease : a role in neurodegeneration ?, inBeyond the Decade of the Brain, Vol. 3 : Neuroprotection in Parkinson's Disease (Olanow W. C. and Jenner P., eds), pp. 227237. Wells Medical Ltd., Royal Tunbridge Wells, U.K.
  • 24
    Hunot S., Boissiere F., Faucheux B., Brugg B., Mouatt-Prigent A., Agid Y., Hirsch E.C. (1996) Nitric oxide synthase and neuronal vulnerability in Parkinson's disease.Neuroscience 72,355363.
  • 25
    Irwin I. & Langston J.W. (1993) MPTP and Parkinson's disease, inNatural and Synthetic Neurotoxins (Harver A. L., ed), pp. 225256. Academic Press, London.
  • 26
    Jenner P. & Olanow W.C. (1996) Oxidative stress and the pathogenesis of Parkinson's disease.Neurology 47 (Suppl. 3) , S161S170.
  • 27
    Lotharius J., Dugan L.L., O'Malley K.L. (1999) Distinct mechanisms underlie neurotoxin-mediated cell death in cultured dopaminergic neurones.J. Neurosci. 19,12841293.
  • 28
    Marriott D.R., Hirst W.D., Ljungberg M.C. (1995) Astrocytes, inNeural Cell Culture—A Practical Approach (Cohen J. and Wilkin G. P., eds), pp. 8596. IRL Press, Oxford.
  • 29
    McGeer E.G. & McGeer P.L. (1997) The role of the immune system in neurodegenerative disorders.Mov. Disord. 12,855858.
  • 30
    McNaught K.S & Brown G.C. (1998) Nitric oxide causes glutamate release from brain synaptosomes.J. Neurochem. 70,15411546.
  • 31
    McNaught K.S & Jenner P. (1999) Extracellular accumulation of nitric oxide, hydrogen peroxide and glutamate in astrocytic cultures following glutathione depletion, complex I inhibition and/or lipopolysaccharide-induced activation.Biochem. Pharmacol. (in press).
  • 32
    McNaught K.S, Thull U., Carrupt P., Altomare C., Cellamare S., Carotti A., Testa B., Jenner P., Marsden C.D. (1996) Nigral cell loss produced by infusion of isoquinoline derivatives structurally releated to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.Neurodegeneration 5,265274.
  • 33
    Mizuno Y., Matuda S., Yoshino H., Mori H., Hattori N., Ikebe S. (1994) An immunohistochemical study on α-ketoglutarate dehydrogenase complex in Parkinson's disease. Ann. Neurol. 35,204210.
  • 34
    Mogi M., Harada M., Kondo T., Riederer P., Inagaki H., Minami M., Nagatsu T. (1994) Interleukin-1β, interleukin-6, epidermal growth factor and transforming growth factor-α are elevated in the brain from parkinsonian patients.Neurosci. Lett. 180,147150.
  • 35
    Morris C.M. & Edwardson J.A. (1994) Iron immunohistochemistry of the substantia nigra in Parkinson's disease.Neurodegeneration 3,277282.
  • 36
    Sagara J., Miura K., Bannai S. (1993) Maintenance of neuronal glutathione by glial cells.J. Neurochem. 61,16721676.
  • 37
    Saggu H., Cooksey J., Dexter D., Wells F.R., Lees A., Jenner P., Marsden C.D. (1989) A selective increase in particulate superoxide dismutase activity in parkinsonian substantia nigra.J. Neurochem. 53,692697.
  • 38
    Sanchez-Ramos J.R., Overvik E., Ames B.N. (1994) A marker of oxyradical-mediated DNA damage (8-hydroxy-2′-deoxyguanosine) is increased in nigro-striatum in Parkinson's disease brain. Neurodegeneration 3,197204.
  • 39
    Savolainen H. (1978) Superoxide dismutase and glutathione peroxidase activities in rat brain.Res. Commun. Chem. Pathol. Pharmacol. 21,173176.
  • 40
    Schapira A.H.V., Mann V.M., Cooper J.M., Dexter D., Daniel S.E., Jenner P., Clark J.B., Marsden C.D. (1990) Anatomic and disease specificity of NADH CoQ1 reductase (complex I) deficiency in Parkinson's disease.J. Neurochem. 55,21422145.
  • 41
    Seaton T.A., Jenner P., Marsden C.D. (1996) Thioctic acid does not restore glutathione levels or protect against the potentiation of 6-hydroxydopamine toxicity induced by glutathione depletion in rats.J. Neural Transm. 103,315329.
  • 42
    Sian J., Dexter D.T., Lees A.J., Daniel S., Agid Y., Javoy-Agid F., Jenner P., Marsden C.D. (1994) Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.Ann. Neurol. 36,348355.
  • 43
    Stewart V.C., Land J.M., Clark J.B., Heales S.J.R. (1998) Comparison of mitochondrial respiratory chain enzyme activities in rodent astrocytes and neurones and a human astrocytoma cell line.Neurosci. Lett. 247,201203.
  • 44
    Wüllner U., Löschmann P., Schulz J.B., Schmid A., Dringen R., Eblem F., Turski L., Klockgether T. (1996) Glutathione depletion potentiates MPTP and MPP+ toxicity in nigral dopaminergic neurones.Neuroreport 7,921923.
  • 45
    Zuddas A., Oberto G., Vaglini F., Fascetti F., Fornai F., Corsini G.U. (1992) MK-801 prevents MPTP-induced parkinsonism in primates.J. Neurochem. 59,133139.